Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;32(1):39-48.
doi: 10.18865/ed.32.1.39. eCollection 2022 Winter.

Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine

Kayla E Cooper  1 , Khadijah E Abdallah  1 , Rebekah S M Angove  2 , Kathleen D Gallagher  2 , Vence L Bonham  1
Affiliations

Navigating Access to Cancer Care: Identifying Barriers to Precision Cancer Medicine

Kayla E Cooper et al. Ethn Dis. .

Abstract

Objective: Precision medicine is revolutionizing cancer treatment. However, there has been limited investigation of barriers patients endure to access precision cancer medicine. This study aims to report the experiences of underserved patient populations with limited access to genomic testing, clinical trials, and precision cancer treatment.

Methods: A mixed-method study was employed to quantitatively evaluate patients (N=300) seeking precision cancer medicine between January 2014- August 2017. Qualitatively, we conducted semi-structured interviews with eight case managers who navigate the health care and health insurance systems to provide patients with access to precision cancer medicine care. All interviews were analyzed to identify themes.

Results: Within our patient cohort, 69% were diagnosed in stage I of cancer disease. Overall, 27 patients (9%) were denied treatment as a final outcome of their case due to insurance denials, 35 patients (12%) died before gaining access to precision cancer medicine, and 6 patients (2%) received precision cancer medicine through clinical trials. Four broad thematic areas emerged from the qualitative analysis: 1) lack of patient, provider and insurer knowledge of precision cancer medicine; 2) barriers to clinical trial participation; 3) lack of patient health literacy; and 4) barriers to timely access to care.

Conclusion: Our combined analyses suggest that both system-level and patient-level barriers limit patient access to precision cancer medicine options. Additionally, we found that these barriers may exist not only for traditionally underserved patients, but also for resourced and insured patients trying to access precision cancer medicine.

Keywords: Barriers to Care; Cancer; Genomics; Precision Cancer Medicine; Underserved.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None declared.

References

    1. Cancer Treatment Centers of America . Targeted Therapies. 2020. Last accessed January 27, 2020 from https://www.cancercenter.com/treatment-options/precision-medicine/ targeted-therapy.
    1. Cancer Treatment Centers of America . Immunotherapy. 2020. Last accessed January 27, 2020 from https://www.cancercenter.com/treatment-options/precision-medicine/immuno...
    1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795. 10.1056/NEJMp1500523 - DOI - PMC - PubMed
    1. Food and Drug Administration . Personalized Medicine at FDA, A Progress & Outlook Report. 2018. Last accessed January 9, 2020 from http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/fil....
    1. National Cancer Institute . NCI Dictionary of Cancer Terms. Last accessed January 27, 2020 from https://www.cancer.gov/publications/dictionaries/cancer-terms.

Publication types

LinkOut - more resources